Certification and Registration
HRIPT Human Repeated Impulse Patch Test
Category:
NEA
What is the HRIPT (Human Repeat Insult Patch Test)?
In our industrialized world, allergic reactions to topical products applied to the skin are becoming increasingly common among consumers.
Whether a true allergic reaction or a simple irritation, the emotional impact experienced by affected consumers is often proportional to the severity of the adverse reaction.
Sensitization refers to the process by which the human body develops an increased allergic response to a substance over time through repeated exposure. It differs from irritation in that it involves an immune response. Due to this immune response, repeated exposure reactions may become more severe and are typically individual-specific.
The Human Repeat Insult Patch Test (HRIPT) is a skin sensitization test designed to evaluate the hypoallergenic claims of topical and cosmetic products. It is widely recognized within the industry and accepted by regulatory authorities worldwide, particularly in North America and the European Union (EU).
Why is HRIPT conducted?
The acronym “HRIPT” or “RIPT” stands for Human Repeat Insult Patch Test or Repeat Insult Patch Test. It is a clinical study or clinical trial, meaning a scientific experiment conducted on human subjects, sometimes referred to as volunteers (or testers for cosmetics and topical products).
Before testing, a preliminary toxicological risk assessment is performed in accordance with current standards. This includes an individual evaluation of product ingredients (toxicological and physicochemical data, purity levels, impurity rates, types of impurities, stability, quality, literature data, etc.) and consideration of the target consumer group (age range, application area, duration of use, etc.).
HRIPT testing is a commonly used industry method to determine the potential for irritation, sensitization, and allergic contact reactions of a product.
In Europe, an equivalent test conducted by the French regulatory authority ANSM is called “Test Clinique Final de Sécurité” (TCFS), or Final Clinical Safety Test. It is included in EU cosmetic safety assessments to confirm that formulations do not contain delayed skin sensitizers.
What are the advantages of conducting HRIPT (Human Repeat Insult Patch Test)?
The primary benefit of HRIPT testing for manufacturers is to determine whether a product formulation can minimize the risk of allergic reactions and/or skin irritation in the target consumer group. Given the increasing number and complexity of ingredients used in topical formulations, exposure to potential allergens is becoming more frequent.
Verifying potential irritation or sensitization before product launch provides a level of safety assurance.
While a zero-risk formulation does not exist, positive clinical study results recognized internationally provide reassurance to R&D, formulation, and marketing teams.
Another advantage of HRIPT testing is that it supports important product claims such as “hypoallergenic,” “dermatologist tested,” “non-irritating,” or “suitable for sensitive skin.”
An additional benefit of HRIPT is that it provides a relatively fast and efficient testing method (approximately 6 weeks), offering a strong return on investment (ROI) before market launch.
When product safety and claim substantiation need to be demonstrated to authorities and business partners, a final report prepared by professionals and signed by dermatologists provides significant value.
HRIPT Patch Test Procedure
HRIPT testing is adapted from the Draize method (animal sensitization testing) and clinical studies published by Kligman and Shelanski in the 1980s. It is a skin patch test typically conducted on a panel of 50, 100, or 200 volunteers. The test involves repeated application of patches containing the test product on the subjects’ backs over a period of six weeks.
Repeated exposure to potential allergens in the formulation (if present) may trigger a series of immune responses in the test subjects, resulting in visible reactions at the application site.
Dermatologists observe, record, and evaluate any reactions to determine whether the product is allergenic and to confirm product safety.
It should be noted that occlusive patch application may enhance penetration of the product and its ingredients into the epidermis.
The patch test is conducted in accordance with Good Clinical Practice (GCP) guidelines. Patches used may be fully occlusive or semi-occlusive. The RIPT is performed under dermatological supervision.
Examples of products suitable for HRIPT testing include:
Anti-aging creams
Moisturizers
Cosmetics
Soaps
Cleansers
Laundry detergents
Textiles
…
SATISFY provides HRIPT (Human Repeat Insult Patch Test) services, including product evaluation, risk analysis, and study protocol development. Please contact SATISFY customer service for more details.
Next page
Next page
Related Information
SATISFY TECH AND SERVICE LLC
SATISFY TECH AND SERVICE LLC delivers full-lifecycle technical solutions for children’s products, hygiene care, protective equipment, furniture, and building materials. Our framework spans compliance pre-assessment, standard upgrading, and risk control. We empower manufacturers and exporters through expert testing, certification, consulting, and standards interpretation.
Contact Us
Address: Room 7D, Building A, Zhongzhou Holdings Financial Center, No. 88 Haide 1st Road, Haizhu Community, Yuehai Subdistrict, Nanshan District, Shenzhen
Phone: 0755-8273-9683
Mobile: 189-2676-2893
Email: info@sdswcn.com
Sales Window
WeChat Applet